Dual inhibition of mTORC1/C2 and HER2 results in maximal antitumor efficacy in preclinical model of HER2+breast cancer resistant to trastuzumab therapy

被引：1
|
作者：
De, Pradip Kr [1 ]
Sun, Yuliang [1 ]
Carlson, Jennifer H. [1 ]
Lin, Xiaoqian [1 ]
Dey, Nandini [1 ]
Leyland-Jones, Brian [1 ]
机构：
[1] Avera Res Inst, Sioux Falls, SD USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-1940
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1940
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Generation, characterization, and maintenance of trastuzumab-resistant HER2+breast cancer cell lines
    Zazo, Sandra
    Gonzalez-Alonso, Paula
    Martin-Aparicio, Ester
    Chamizo, Cristina
    Cristobal, Ion
    Arpi, Oriol
    Rovira, Ana
    Albanell, Joan
    Eroles, Pilar
    Lluch, Ana
    Madoz-Gurpide, Juan
    Rojo, Federico
    AMERICAN JOURNAL OF CANCER RESEARCH, 2016, 6 (11): : 2661 - +
  • [42] Efficacy of pertuzumab/trastuzumab /paclitaxel over standard trastuzumab/paclitaxel therapy for HER2+breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
    Buxton, Meredith
    DeMichele, Angela M.
    Chia, Stephen
    van't Veer, Laura
    Chien, Jo
    Wallace, Anne
    Kaplan, Henry
    Lang, Julie
    Yee, Douglas
    Isaacs, Claudine
    Moulder, Stacy
    Albain, Kathy
    Boughey, Judy
    Kemmer, Kathleen
    Haley, Barbara
    Minton, Susan
    Forero, Andres
    Nanda, Rita
    Elias, Anthony
    Korde, Larissa
    Viscuzi, Rebecca
    Rugo, Hope
    Schwab, Richard
    Symmans, Fraser
    Paoloni, Melissa
    Hylton, Nola
    Hogarth, Michael
    Lyandres, Julia
    Perlmutter, Jane
    Sanil, Ashish
    Yau, Christina
    Esserman, Laura
    Berry, Don
    CANCER RESEARCH, 2016, 76
  • [43] Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+breast cancer: preliminary results
    Sorace, Anna G.
    Quarles, C. Chad
    Whisenant, Jennifer G.
    Hanker, Ariella B.
    McIntyre, J. Oliver
    Sanchez, Violeta M.
    Yankeelov, Thomas E.
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 155 (02) : 273 - 284
  • [44] Inhibition of HER2 and IGF2 triggers cell death in trastuzumab-resistant HER2 positive JIMT1 cells
    Helu, Xousaen M.
    De Leon, Daisy
    CANCER RESEARCH, 2014, 74 (19)
  • [45] Sparing chemotherapy with dual HER2 blockade in combination with endocrine therapy for advanced HER2 positive breast cancer
    Werutsky, Gustavo
    Reinert, Tomas
    Fay, Andre Poisl
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S573 - S576
  • [46] A pilot study utilizing a HER2 directed dendritic cell vaccine during neoadjuvant therapy of HER2+breast cancer
    Soliman, Hatem
    Hogue, Deanna
    Han, Hyo
    Khong, Hung
    Costa, Ricardo
    Armaghani, Avan
    Muller, Axia Soyano
    Khakpour, Nazanin
    Lee, Marie C.
    Kiluk, John
    Czerniecki, Brian
    CANCER RESEARCH, 2020, 80 (04)
  • [47] In vivo inhibition of metastatic HER2 positive trastuzumab resistant breast cancer using engineered destabilized 3UTR ARE of HER2 improves survival outcomes
    Awah, Chidiebere U.
    Mun, Joo Sun
    Boylu, Baris
    Paragodaarachchi, Alooka
    Ochu, Chika
    Matsui, Hiroshi
    Ogunwobi, Olorunseun O.
    CANCER RESEARCH, 2023, 83 (07)
  • [48] Trastuzumab Deruxtecan in HER2-Positive Breast Cancer with HER2 Loss After Dual-Target Adjuvant Therapy: A Case Report
    Ouyang, Wei
    Liu, Yixin
    Cao, Jun
    Chen, Jinghua
    AMERICAN JOURNAL OF THERAPEUTICS, 2025, 32 (02) : e172 - e176
  • [49] Dual HER2 Targeted Therapy With Pyrotinib and Trastuzumab in Refractory HER2 Positive Metastatic Colorectal Cancer: A Result From HER2-FUSCC-G Study
    Chang, Jinjia
    Xu, Midie
    Wang, Chenchen
    Huang, Dan
    Zhang, Zhe
    Chen, Zhiyu
    Zhu, Xiaodong
    Li, Wenhua
    CLINICAL COLORECTAL CANCER, 2022, 21 (04) : 347 - 353
  • [50] EFFICACY OF HER2-TARGETED THERAPY FOR HER2 POSITIVE BREAST CANCER ACCORDING TO HR STATUS
    Murata, T.
    Takahashi, M.
    Hayashida, T.
    Hirose, S.
    Jinno, H.
    Kitagawa, Y.
    BREAST, 2013, 22 : S104 - S104
12345